Solabrgron (AltheRx) success in Phase II for Overactive Bladder

Positive results are anounced by AltheRx Pharma from its Phase II study of Solabegron in Overactive Bladder (OAB) at the European Association of Urology Congress in Paris (Abstract #685).The Phase II multi-center, randomized, double-blind, placebo-controlled, parallel group study compared two dosage strengths of Solabegron (50 mg and 125 mg) to placebo in 258 women with moderate to severe OAB symptoms (averaging 4.5 incontinence episodes per day), more than half of whom had unsuccessful prior treatment with muscarinic agents. Solabegron 125 mg, dosed twice daily over 8 weeks, produced a 65.6 percent reduction from baseline in incontinence episodes, a statistically significant adjusted mean difference from placebo of 21 percent (p=0.025). Patients treated with Solabegron also reported a significant reduction in the frequency of urination (-0.8; p=0.036), and a marked and significant increase in the volume of urine voided (+27%; p<0.001) both compared to placebo. solabegron was acquired by altherx from gsk in 2011.>